Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fate Therapeutics launched through $14.6mm Series A

Executive Summary

Fate Therapeutics (adult stem cell biology) was recently launched through a two-tranche $14.6mm Series A round backed by Arch Venture Partners, Polaris Venture Partners, OVP Venture Partners, and Venrock. The start-up has a small-molecule platform that modulates adult stem cells to mimic the beneficial characteristics of embryonic stem cells.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies